Hepatitis C Center

It is estimated that 3.2 million Americans are infected with Hepatitis C virus, the majority infected with genotype 1.  Of these, less than half are aware of their diagnosis, and fewer are treated.  We are at the dawn of a new era in Hepatitis C treatment, with the first new medications in 10 years approved by the Federal Drug Administration (FDA) in the spring of 2011.  With these approvals comes a significantly increased anticipated volume of patients who will seek or be recommended to undergo treatment with anti-viral medication including pegylated interferon, ribavirin, and a new protease inhibitor.  While efficacy of treatment has risen, so too has the complexity of treating Hepatitis C.  The Jefferson Hepatitis C Center, created in 2011 under the direction of Jonathan Fenkel, MD, aims to provide a coordinated approach to the delivery of care to patients with Hepatitis C and patients with coinfection of Hepatitis C and Hepatitis B and/or HIV.  

• Biweekly outpatient Hepatitis C treatment clinic
• Active clinical trials program
• Multidisciplinary monthly HIV/HCV coinfection clinic
  • Hepatology, Infectious Diseases, Pharmacy
• Expert liver pathologists and radiologists
• Co-management opportunities for community physicians – tailored program to meet individual provider and patient needs
• Expert Consultations including detailed plan highlighting potential drug interactions and treatment considerations.

Contact Information:
Jonathan Fenkel, MD
Director, Jefferson Hepatitis C Center
132 S. 10th Street
Suite 480, Main Building
Philadelphia, PA 19107
(215) 955-8900

Brandy Rich, MA
Clinical Coordinator
Jefferson Hepatitis C Center
(215) 955-8900